GEM 21S
Alternative Names: B-TCP Plus; GEM 21S; GEM21S; GEMESISLatest Information Update: 03 Nov 2022
At a glance
- Originator ZymoGenetics
- Developer Luitpold Pharmaceuticals
- Class Growth factors
- Mechanism of Action Osteogenesis stimulants; Platelet-derived growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bone disorders
- No development reported Osteonecrosis